Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.

TOBIN JAMES R

ZARRILLI STEPHEN T

Huller Kelly

Norwalk Leslie V

Kline Kyle

Davidar David D

Hinge Health (HNGE) raised its 2026 revenue guidance to $856-$860M following a 53% Q2 revenue jump to $212.8M. The company is expanding beyond its core MSK platform into Migraine Care (450 clients, 5M lives) and acquiring Cylinder Health for $105M to accelerate GI expansion. While growth prospects remain strong with a 30.6% expected growth rate, continued product investments and integration costs could temper margin expansion.

Reasons to Hold Hinge Health Stock in Your Portfolio for Now

Boston Scientific plans multiple product launches through 2028 across Interventional Cardiology, EP, and CRM segments, including SEISMIQ 4CE, FARAWAVE Ultra, and PRECEDENT platforms. However, the company expects flat global EP growth in H2 2026 due to competitive pressures, with momentum expected to return in H2 2027. BSX stock has underperformed the industry over the past 12 months and carries a Zacks Rank #5 (Strong Sell) rating.

Will Boston Scientific's Upcoming Launches Fuel the Next Growth Phase?

Avantor has expanded its RIM single-use bioprocessing portfolio across the Asia Pacific region with local manufacturing in China. The expansion aims to improve supply reliability and customization for regional biopharma customers. The company's Bioscience & Medtech Products segment showed double-digit order growth and a 1.1x book-to-bill ratio in Q2 2026, supporting long-term bioprocessing growth.

Avantor Broadens RIM Single-Use Bioprocessing Reach in APAC

West Pharmaceutical Services (WST) is well-positioned for growth driven by strong demand for high-value products (HVPs), expanding biologics exposure, and regulatory-driven Annex 1 conversions. The company expects about 200 basis points of revenue growth from Annex 1 upgrades in 2026. However, weak West Vantage segment performance due to a cyber incident and commodity inflation remain near-term concerns. The stock has gained 33.1% year-to-date.

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

Penumbra (PEN) reported Q2 2026 revenues up 14.9% driven by thrombectomy and embolization products, with international sales growing 7.6% across 100+ countries. However, SG&A expenses grew faster than revenues at 24.1%, causing operating margins to compress. Foreign exchange exposure and macroeconomic sensitivity pose risks, though the company maintains a Zacks Rank #3 (Buy) rating with shares up 21.1% over the past year.

Reasons to Retain Penumbra Stock in Your Portfolio for Now

BrightSpring Health Services (BTSG) is rated a Strong Buy with strong momentum in Provider Services and expanding specialty pharmacy and infusion operations. However, the company faces near-term margin pressure from Inflation Reduction Act reimbursement cuts and execution risks from multiple integrations and geographic expansions through 2026.

Globus Medical (GMED) Stock Price, Analysis & Trade Signals